Psychedelics have been studied for treating AUD, but supporting controlled trials are slim. There's much more substantial ...

Among inpatients at an academic center, serial adjunctive ketamine infusions were no more effective at treating major depression than midazolam, according to a randomized clinical trial published in ...

The expanded indication for the oral atypical antipsychotic now includes adjunctive use with antidepressants in adults with major depressive disorder.

Creatine supplementation may modestly reduce depressive symptoms, but the effect is small, uncertain, and likely influenced ...

The FDA approved lumateperone (Caplyta) as an adjunctive therapy with antidepressants for the treatment of major depressive ...

Biohaven (BHVN) downgraded after FDA setback for VYGLXIA. Learn key risks, pipeline shifts, and what investors should watch ...

The shift from summer to fall is magical — complete with pretty leaves, less sunburn and good ol’ sweater weather. The ...

Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s ...

The U.S. Food and Drug Administration has approved the expanded use of Johnson & Johnson's drug Caplyta as an add-on treatment for adults with major depressive disorder, the company said on Thursday.

HealthDay News — Serial adjunctive ketamine infusions are not more effective than serial midazolam infusions in reducing depressive symptoms in patients receiving inpatient psychiatric care for a ...

Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...

The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...